Monetary Policy and Economic Measures - The central bank governor Pan Gongsheng stated that a moderately loose monetary policy will continue in 2026, utilizing various tools such as reserve requirement ratio cuts and interest rate reductions to maintain ample liquidity [1] - The first batch of 936 billion yuan of ultra-long special government bonds has been allocated to support equipment renewal across various sectors, expected to drive total investment exceeding 460 billion yuan [2] - The central bank will conduct a 900 billion yuan MLF operation on January 23, net injecting 700 billion yuan into the market, marking the 11th consecutive month of increased operations [2] Consumer and Investment Trends - The six major state-owned banks collectively announced the implementation of personal consumption loan interest subsidy policies, allowing some high-quality clients to enjoy effective interest rates as low as 2%, even lower than current housing loan rates [1] - Public funds have focused their fourth-quarter 2025 positions on core sectors such as electronics and power equipment, with Zhongji Xuchuang becoming the largest holding stock [1] Market Performance - The A-share market saw a slight increase, with the Shanghai Composite Index rising 0.14% to 4122.58 points, and the Shenzhen Component Index increasing by 0.5% [3] - The Hong Kong stock market also experienced minor fluctuations, with the Hang Seng Index rising 0.17% to 26629.96 points, while southbound funds recorded a net purchase of 5.166 billion HKD [3] Corporate Developments - Alibaba Group has decided to support its chip subsidiary "Pingtouge" for independent listing, with plans for restructuring to establish it as a mixed-ownership enterprise [4] - Blue Arrow Aerospace's IPO status has changed to "inquired," aiming to raise 7.5 billion yuan to become the "first stock in commercial aerospace" [4] - Yuanqi Forest is reportedly considering a Hong Kong listing, although the company has stated there are currently no IPO plans [4] Regulatory and Policy Updates - The State Administration for Market Regulation has issued a red card for the first time in the public utility sector, prohibiting a merger case involving gas companies in Foshan [7] - Nine departments jointly issued opinions to promote high-quality development in the pharmaceutical retail industry, encouraging mergers and acquisitions among retail pharmacies [7] - The Ministry of Civil Affairs and the Ministry of Finance announced a subsidy program for elderly individuals with moderate to severe disabilities, set to be implemented nationwide starting January 1, 2026 [2]

Macro and Strategy Research - The US economy shows strong internal momentum with a 0.3% month-on-month increase in personal consumption expenditures adjusted for inflation in November 2025, marking the highest growth rate since the second half of 2025 [2] - In Europe, inflation dropped below 2% year-on-year in December 2025, indicating easing pressure, supported by labor costs and year-end consumption [3] - Domestic economic growth in China for 2025 is expected to meet targets despite a slowdown in the fourth quarter, with net exports providing structural support in early 2026 [3] Fixed Income Research - The bond market continues to show signs of recovery, with mid- to long-term bonds performing well, driven by a strong equity market and manageable bank liability pressures [5][7] - The issuance of special bonds increased significantly, with a total of 56 bonds issued, amounting to 619.1 billion yuan during the reporting period [7] - The overall bond market is characterized by a recovery trend, with the yield on 7-year government bonds declining the most [7] Industry Research - Nine departments in China have issued opinions to promote high-quality development in the pharmaceutical retail industry, indicating potential benefits for leading chain pharmacies and an expected operational turning point [10][12] - The SW pharmaceutical industry index shows a price-to-earnings ratio of 52.01, with a valuation premium of 266% relative to the CSI 300 index [11] - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring segments like small nucleic acids [12]

Group 1 - The core point of the article is that Fosun Pharma announced the pledge and release of part of its A-share holdings by its controlling shareholder, Shanghai Fosun High Technology (Group) Co., Ltd. [1] - The number of shares pledged in this transaction is 32,000,000 shares [1]

Core Viewpoint - Fosun Pharma (02196) announced that its controlling shareholder, Fosun High Technology Group Co., Ltd., has pledged and released part of its A-share holdings in the company [1] Group 1 - The number of pledged shares is 32 million, which accounts for 3.33% of the shares held by the controlling shareholder and 1.20% of the total shares of the company [1] - The controlling shareholder released 103 million shares from pledge on January 22, 2026, leaving 476 million shares still pledged [1]

Core Viewpoint - Fosun Pharma announced a plan to spin off its subsidiary Fosun Antigen for a listing on the Hong Kong Stock Exchange, aiming to enhance financing channels and market competitiveness, despite the current downturn in the domestic vaccine industry and Fosun Antigen's poor financial performance [1][3]. Financial Performance - Fosun Antigen's revenue is projected to decline significantly from 461 million yuan in 2022 to 97.42 million yuan in 2024, with a net profit turning from a profit of 86.64 million yuan to a loss of 123.38 million yuan [3]. - The company's total assets as of December 31, 2024, are reported at 345.86 billion yuan, with a debt-to-asset ratio of 33.87% [3]. - The net cash flow from operating activities is negative at -105.29 million yuan for 2024, indicating financial strain [3]. Market Context - The domestic vaccine industry is currently facing challenges, with significant price competition among established products, leading to revenue declines for major players [6][9]. - The market for flu vaccines and rabies vaccines is particularly competitive, with price cuts from leading companies impacting overall sales [6][9]. Product Pipeline - Fosun Antigen has a limited product lineup, with four vaccines currently on the market, including rabies and flu vaccines, which are in a crowded market [5][6]. - The company is developing several vaccines, including the 13-valent and 24-valent pneumococcal conjugate vaccines, but lacks progress compared to competitors [7][10]. Competitive Landscape - The pneumococcal vaccine market is becoming increasingly competitive, with multiple players entering the space, leading to declining sales for existing products [9][12]. - Fosun Antigen's 24-valent pneumococcal vaccine is still in the early clinical trial phase, while competitors have advanced further in their development [10][12].

Core Viewpoint - Fosun Pharma (02196) announced that its controlling shareholder, Fosun High Technology Group Co., Ltd., has pledged and released part of its A-share holdings in the company [1] Group 1 - The number of pledged shares is 32 million, which accounts for 3.33% of the shares held by the controlling shareholder and 1.20% of the total shares of the company [1] - The controlling shareholder released 103 million shares from pledge on January 22, 2026, with 476 million shares remaining pledged [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 股東部分股份質押及解除質押的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2026 年1 月2 3 日 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 * ...

上海复星医药（集团）股份有限公司 关于股东部分股份质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ● 截 至 2026 年 1 月 22 日 收 市 ， 控 股 股 东 复 星 高 科 技 持 有 本 公 司 961,424,455 股股份（其中：A 股 889,890,955 股、H 股 71,533,500 股），约占 截至当日收市本公司股份总数的 36.00%。本次质押及解除质押后，复星高科技 质押本公司股份数量余额为 476,275,000 股（均为 A 股），约占截至当日收市本 公司股份总数的 17.84%。 证券代码：600196 股票简称：复星医药 编号：临 2026-011 ● 截至 2026 年 1 月 22 日收市，控股股东复星高科技及其一致行动人（即 复星高科技董监高、复星国际有限公司及其董高<包括本公司实际控制人>，下同） 合计持有本公司967,812,180股股份（其中：A股890,278,680股、H股77,533,500 股），约占截至当日收市本公 ...

复星医药公告称，截至2026年1月22日收市，控股股东复星高科技持有公司9.61亿股，占比36.00%；其 及其一致行动人合计持有9.68亿股，占比36.24%。当日，复星高科技质押3200万股，占其所持股份数比 例3.33%，用于偿还债务；解除质押1.03亿股，占其所持本公司股份数的比例10.68%。本次质押及解除 质押后，复星高科技质押公司股份数量余额为4.76亿股，占公司股份总数的17.84%，占其及其一致行动 人所持有公司股份数的49.21%。预计未来一年和六个月内分别有3.38亿股、1.95亿股质押到期，对应融 资余额31.54亿元、17.69亿元。 ...

1月23日，港股早盘高开低走，午后低位窄幅震荡，截止收盘，恒生指数涨0.45%报26749.51点，恒生科 技指数涨0.62%报5798.01点，国企指数涨0.51%报9160.81点，红筹指数跌0.16%报4217.25点。 盘面上，大型科技股多数走高，阿里巴巴涨2.25%，腾讯控股跌0.42%，京东集团涨0.79%，小米集团涨 2.84%，网易跌0.96%，美团涨0.57%，快手涨2.72%，哔哩哔哩涨2.18%；商业航天概念大涨，钧达股份 涨超51%，亚太卫星涨超14%，金风科技涨超10%；光伏太阳能股涨幅居前，凯盛新能涨超14%；黄金 板块上涨，紫金黄金国际涨超8%，赤峰黄金涨超7%；中国黄金国际、老铺黄金涨超6%；新消费概念股 上涨，泡泡玛特涨6.6%；欧美针对格陵兰的紧张关系降温，石油股全天低迷，航空股、煤炭股、纸业 股、建材水泥股、内房股多数走低。 企业新闻 保诚(02378.HK)：斥资约3.75亿美元将其于PAMB的股份权益增加至70%，标的公司在马来西亚的传统 寿险业务。 南京熊猫电子股份(00553.HK)：预计2025年度归母净利润1000万元到1500万元，同比扭亏为盈。 德昌电机控 ...